Nuvation Bio (NUVB) Total Non-Current Liabilities (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Total Non-Current Liabilities of $290.7 million for Q1 2026, up 313.92% year-over-year from $70.2 million in Q1 2025, and up 1.55% quarter-over-quarter from $286.2 million in Q4 2025.
Nuvation Bio (NUVB) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Total Non-Current Liabilities for 7 consecutive years, with $290.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 313.92% year-over-year to $290.7 million; the TTM figure through Mar 2026 stood at $290.7 million (up 313.92% YoY), while the FY2025 annual figure was $286.2 million, up 282.75% from the prior year.
- Total Non-Current Liabilities grew to $290.7 million in Q1 2026 per NUVB's latest filing, from $286.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $290.7 million in Q1 2026 and bottomed at $15.3 million in Q1 2023.
- Historically, Total Non-Current Liabilities has averaged $91.9 million across 5 years, with a median of $25.0 million in 2022.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities plunged 36.84% — and 2024, when it jumped 367.14%.
- Nuvation Bio's Total Non-Current Liabilities stood at $16.2 million in 2022, then decreased by 1.27% to $16.0 million in 2023, then surged by 367.14% to $74.8 million in 2024, then soared by 282.75% to $286.2 million in 2025, then advanced by 1.55% to $290.7 million in 2026.
- Business Quant data shows NUVB's Total Non-Current Liabilities at $290.7 million in Q1 2026, $286.2 million in Q4 2025, and $273.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 490.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 490.64 Mn |
| Mar 31, 2026 | 290.68 Mn |
| Dec 31, 2025 | 286.24 Mn |
| Sep 30, 2025 | 273.94 Mn |
| Jun 30, 2025 | 271.97 Mn |
| Mar 31, 2025 | 70.23 Mn |
| Dec 31, 2024 | 74.79 Mn |
| Sep 30, 2024 | 67.96 Mn |
| Jun 30, 2024 | 61.22 Mn |
| Mar 31, 2024 | 17.27 Mn |
| Dec 31, 2023 | 16.01 Mn |
| Sep 30, 2023 | 18.69 Mn |
| Jun 30, 2023 | 15.81 Mn |
| Mar 31, 2023 | 15.28 Mn |
| Dec 31, 2022 | 16.22 Mn |
| Sep 30, 2022 | 17.38 Mn |
| Jun 30, 2022 | 25.03 Mn |
| Mar 31, 2022 | 23.53 Mn |
| Dec 31, 2021 | 19.12 Mn |
| Sep 30, 2021 | 13.49 Mn |